Earnings ·
CVRx reported second quarter 2026 total revenue of $15.7 million, a 16% increase year-over-year, driven by U.S. sales…
CVRXCVRx, Inc.
CVRx reported second quarter 2026 total revenue of $15.7 million, a 16% increase year-over-year, driven by U.S. sales growth to $14.8 million and an expansion in active implanting centers to 258. The company announced updated full-year 2026 guidance, projecting total revenue between $58.0 million and $60.0 million and operating expenses between $99.0 million and $101.0 million, citing headwinds from fewer sales territories and lower productivity. Additionally, Humana issued a Medicare Advantage coverage policy for Barostim therapy effective May 1, 2026. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases.